GEN-MKT-18-7897-A
Apr 16, 2019 | Blogs, Technology | 0 comments
Every decision you make requires a number
As a pharmaceutical scientist, you understand the challenges in getting a new drug through the discovery and development pipeline. As an innovation partner in mass spectrometry, SCIEX works continuously with you, our customers, to provide solutions that meet those challenges. Our focus is on getting you the numbers you need to make informed decisions.
Working with complex sample matrices, you need technology that allows you to see everything in your sample, no matter how high or low the levels. Tools that can detect low pg/mL levels (or lower) can analyze a wide mass range of compounds (across five orders of magnitude) and can resolve similar or even isobaric compounds, enable you to get the quality data that allow your lab to move forward. And you need to move quickly, without wasting time on repairs and troubleshooting.
Conquering your challenges
Since the first commercially available electrospray triple-quadrupole instrument, SCIEX has delivered innovative mass spectrometry-based solutions. Today, we continue that legacy of innovation and our commitment to delivering the technology you need to move past the challenges that slow you down.
As we mark the 30th anniversary of the industry-changing API III LC-MS/MS system in 2019, we are revisiting the basics of answering: Why quant? Why SCIEX for quant?? We‘ll examine how our mass spectrometry innovation addresses the challenges you struggle with the most, today– exploring what you need from the technology that helps you achieve your goals. Now, let’s talk a little bit about the four key pillars we use to characterize those goals: Sensitivity, Selectivity, Reproducibility, and Robustness.
SensitivityYou need a mass spectrometer that sees what’s in your sample. Superior sensitivity is a tool for the situations you face every day:
Read the blog, ‘Sensitivity, It’s at the Very Heart of Who We Are’ >
SelectivityPowerful selectivity keeps your target compounds from being obscured by unexpected interferences:
Read the blog, ‘Detect the Signal, Not the Noise’ >
ReproducibilityIndustry leaders discuss their results clearly and with confidence. Knowing you’re presenting reproducible data makes those discussions easier:
Read the blog, ‘Improving Precision’ >
RobustnessDowntime costs money and keeps you from getting to market on time. A robust system helps solve that problem:
Read the blog, ‘Robust by Design. Built-in.’ >
To see how SCIEX technology innovations impact pharmaceutical analysis, explore the applications and techniques in our ebook.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network